Biopharma / Medtech Reports

February 19, 2025

Renal Denervation: Medicare Coverage at 10%-20% of TAM?

•

John Leppard

MDT (US), OTSKY (US)
February 8, 2025

Life Science Tools: NIH Indirect Cost Cut Risks

•

John Leppard

AVTR (US), BRKR (US), ILMN (US), QGEN (US), TMO (US), TXG (US), WAT (US)
February 6, 2025

[EXAS, GH, GRAL] Multi-Cancer Coverage: Take 2

•

John Leppard

EXAS (US), GH (US), GRAL (US)
January 29, 2025

RFK Risks Post-Confirmation Hearing

•

John Leppard

BRKR (US), CNC (US), CVS (US), GSK (LSE), ILMN (US), MOH (US), NVO (US), SNY (US)
January 21, 2025

Guardant (GH) Reveal Medicare Coverage FAQ

•

John Leppard

GH (US)
January 17, 2025

[NVO, BHC, TEVA] Quantifying IRA Price Negotiation Risks

•

John Leppard

ABBV (US), AMGN (US), BHC (US), BMY (US), GSK (US), LLY (US), NVO (US), TEVA (TA)
January 13, 2025

Medtronic: Medicare RDN Coverage in 4Q24

•

John Leppard

MDT (US)
January 13, 2025

Inspire V Payment & Coverage Quick Take

•

John Leppard

INSP (US)
January 12, 2025

Diagnostics’ New Supreme Court Risk

•

John Leppard

EXAS (US), GH (US), HOLX (US), MYGN (US), NEO (US), OSUR (US)
January 10, 2025

Medtronic (MDT): Renal Denervation Coverage Read-Through?

•

John Leppard

MDT (US)